Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivelsiran for early-stage Down syndrome-associated Alzheimer's disease
2025-523390-42-00Phase 2Authorised
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Aug 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in dementia due to Down syndrome (DS-AD) comparing Mivelsiran with Placebo (2 arms). Planned start Aug 2026; status: authorised.
02
Drugs
mivelsiran
03
Conditions
dementia due to Down syndrome (DS-AD)
Beyond the preview
Go deeper on 2025-523390-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523390-42-00.